Eric Pauwels Sells 1,378 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels sold 1,378 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $69,037.80. Following the completion of the sale, the chief executive officer now owns 85,427 shares in the company, valued at approximately $4,279,892.70. This represents a 1.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Eric Pauwels also recently made the following trade(s):

• On Tuesday, January 7th, Eric Pauwels sold 1,599 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $72,498.66.

PTC Therapeutics Stock Up 0.6 %

PTCT stock opened at $50.69 on Friday. PTC Therapeutics, Inc. has a 52-week low of $24.00 and a 52-week high of $54.16. The stock’s fifty day simple moving average is $46.67 and its 200-day simple moving average is $41.56. The stock has a market capitalization of $3.91 billion, a price-to-earnings ratio of -8.53 and a beta of 0.62.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Robert W. Baird upped their price target on PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. StockNews.com lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Royal Bank of Canada upped their target price on PTC Therapeutics from $60.00 to $63.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. Wells Fargo & Company upped their target price on PTC Therapeutics from $56.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. Finally, Cantor Fitzgerald upped their target price on PTC Therapeutics from $76.00 to $113.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Three research analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $58.85.

Institutional Investors Weigh In On PTC Therapeutics

Hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC boosted its holdings in shares of PTC Therapeutics by 78.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 270 shares during the last quarter. Sterling Capital Management LLC raised its position in shares of PTC Therapeutics by 424.4% in the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 522 shares during the period. Venturi Wealth Management LLC purchased a new position in shares of PTC Therapeutics in the 4th quarter worth $68,000. GF Fund Management CO. LTD. purchased a new position in shares of PTC Therapeutics in the 4th quarter worth $73,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PTC Therapeutics in the 4th quarter worth $77,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.